TITLE

Targeting Divalent Metal Ions at the Active Site of the HIV-1 RNase H Domain: NMR Studies on the Interactions of Divalent Metal Ions with RNase H and Its Inhibitors

AUTHOR(S)
Jiangli Yan; Haihong Wu; Tom, Tiffany; Brodsky, Oleg; Maegley, Karen
PUB. DATE
October 2011
SOURCE
American Journal of Analytical Chemistry;Oct2011, Vol. 2 Issue 6, p639
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
HIV-1 reverse transcriptase (RT) RNase H (HIV-RH) is a key target of anti-AIDS drugs. Metal-chelating compounds are an important class of chemicals in pharmacological drug discovery, especially in relation to HIV-RT and the highly-related HIV-integrase. The correlation between the metal-chelating properties and enzyme activities of the metal chelators is always of high scientific interest, as an understanding of this may accelerate the rational optimization of this class of inhibitors. Our NMR data show that Mg2+ and Ca2+ bind specifically to the active site of the RNase H domain and two Mg2+ ions sequentially bind one molecule of RNase H. We also demonstrate here, using saturated and unsaturated tricyclic N-hydroxypyridones designed to block the active site, that the primary binding sites and affinities of divalent metal ions are correlated with the structures of the chelating motifs. Chemical shift perturbation studies of protein/metal-ion/compound ternary complexes also indicate that divalent metal ions play important roles for the specific interaction of the compounds with the RNase H active site.
ACCESSION #
71420941

 

Related Articles

  • New Therapies in HIV/AIDS Treatment. Garmany, Justin; Kramer, Richard // Drug Formulary Review;Jun2008 Supplement, Vol. 24, p1 

    The article focuses on the developments in therapies for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). It emphasizes the positive effect of highly reactive antiretro-viral therapy (HAART) on the quality of life, T cell count and survival in HIV patients. The...

  • Universal modular system for in vitro screening of potential inhibitors of HIV-1 replication. Prokofjeva, M.; Orlova, N.; Gornostaeva, A.; Shulgin, A.; Nikitenko, N.; Senchenko, V.; Lebedev, T.; Spirin, P.; Riecken, K.; Fehse, B.; Stocking, C.; Prassolov, V. // Molecular Biology;Mar2014, Vol. 48 Issue 2, p297 

    A system based on recombinant lentiviral vectors has been designed for safe screening of potential anti-HIV drugs. The system can be used to evaluate the sensitivity of HIV-1 reverse transcriptase and integrase (wild-type as well as mutant forms of these enzymes detected in drug-resistant virus...

  • Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012. Hurt, Christopher B.; Sebastian, Joseph; Hicks, Charles B.; Eron, Joseph J. // Clinical Infectious Diseases;Feb2014, Vol. 58 Issue 3, p423 

    Among 3012 patients with clinical specimens submitted for integrase resistance genotyping from January 2009 to December 2012, 15.6% harbored ≥1 “major” integrase inhibitor mutation. Intermediate or high-level dolutegravir resistance was predicted for 6.4% (41.2% of those with...

  • New anti-HIV class could lower cost of triple whammy. McCann, Jean // Drug Topics;8/19/96, Vol. 140 Issue 16, p42 

    Evaluates cost efficiency and effectiveness of a new class of anti-AIDS drugs for use as part of the triple therapy regiments being recommended by physicians in the United States. Mechanism of action of non-nucleoside reverse transcriptase (RT) drugs nevirapine and delaviridine; Advantages;...

  • CNE/CME QUESTIONS.  // AIDS Alert;May2010, Vol. 25 Issue 5, p59 

    A quiz is presented related to medical care for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) patients.

  • CNE/CME questions.  // AIDS Alert;Feb2009, Vol. 24 Issue 2, p23 

    A quiz concerning the treatment for HIV and AIDS is presented.

  • Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms. DUGGAN, JOAN M.; AKPANUDO, BARBARA; SHUKLA, VIPUL; GUTTERSON, GLEN; EITNIEAR, LINDSEY; SAHLOFF, ERIC G. // American Journal of Health-System Pharmacy;9/15/2015, Vol. 72 Issue 18, p1555 

    Purpose. Evidence-based guidance is presented to assist clinicians in selecting alternative formulations of antiretroviral (ARV) agents for patients with human immunodeficiency virus (HIV) infection who are unable to swallow tablets or capsules. Summary. The inability to take medications in...

  • Denovo design and optimization of novel inhibitor molecules for HIV integrase. Jain, Shailesh; Bari, S. B.; Namdeo, Rajnikant // International Journal of ChemTech Research;Apr-Jun2011, Vol. 3 Issue 2, p716 

    Infection of HIV virus; and AIDS is well understood in human and is characterized by a decrease in the number of helper T cells, which causes a severe immunodeficiency that leaves the body susceptible to a variety of potentially fatal infections. In the present study we chose integrase protein,...

  • Hologram Quantitative Structure-Activity Relationships Investigations of Non-nucleoside Reverse Transcriptase Inhibitors. Pungpo, Pormpan; Hannongbua, Supa; Wolschann, Peter // Current Medicinal Chemistry;Sep2003, Vol. 10 Issue 17, p1661 

    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as TIBO, HEPT and dipyridodiazepinone are effective against HIV-1 RT. These NNRTIs are chemically and structurally diverse, but they all bind to a common allosteric site of HIV-1 RT. These inhibitors exhibit high potency, low...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics